Corient Private Wealth’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Corient Private Wealth’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,076	Closed	-$2.58M	–	2201
2023 Q1	$2.58M	Sell	24,076 -2,205	-8%	-$254K	0.01%	765
2022 Q4	$2.89M	Buy	+26,281	New	+$1.7M	0.01%	619

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Corient Private Wealth's RXDX Position: Q2 2023 in Review

Corient Private Wealth sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 24,076 shares — an estimated $2.58M sold.

Corient Private Wealth first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $2.89M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Corient Private Wealth reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Corient Private Wealth sold 24,076 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.58M.
Corient Private Wealth first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Corient Private Wealth's Prometheus Biosciences, Inc. Common Stock position peaked at $2.89M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Corient Private Wealth's 13F filing for Q2 2023, filed 10 Aug 2023.